Nivolumab (anti-PD-1) is a monoclonal antibody used as an immune checkpoint inhibitor that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby restoring T-cell-mediated antitumor immunity; it is approved by the U.S. FDA and the European Medicines Agency (EMA) for the treatment of renal cell carcinoma; it enhances T-cell responses and cytokine production in vitro in the presence of T-cell receptor stimulation; it is also used in the treatment of various cancers by harnessing the patient's immune system to target tumor cells.